Alumis to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
核心洞察
Alumis Inc. will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis (搜索) on January 6, 2026.
The company will host a conference call and webcast at 8:00 a.m. ET following the data announcement to discuss the results with investors and stakeholders.
Envudeucitinib is an oral tyrosine kinase 2 (搜索) inhibitor being developed for systemic immune-mediated disorders including plaque psoriasis and systemic lupus erythematosus (搜索).
Alumis Inc. (Nasdaq: ALMS) announced that it will report topline data from the Phase 3 ONWARD clinical program evaluating envudeucitinib in patients with moderate-to-severe plaque psoriasis (搜索) on Tuesday, January 6, 2026. The South San Francisco-based late-stage biopharma company will follow the data announcement with a conference call and webcast at 8:00 a.m. ET to discuss the results.
Phase 3 ONWARD Program Results
The ONWARD clinical program represents a pivotal study for envudeucitinib, formerly known as ESK-001, in treating moderate-to-severe plaque psoriasis (搜索). The topline data release will provide crucial insights into the efficacy and safety profile of this oral tyrosine kinase 2 (搜索) inhibitor in this patient population.
Envudeucitinib Development Pipeline
Envudeucitinib is part of Alumis's pipeline of oral tyrosine kinase 2 (搜索) inhibitors designed for treating systemic immune-mediated disorders. Beyond moderate-to-severe plaque psoriasis (搜索), the company is also developing envudeucitinib for systemic lupus erythematosus (搜索). The company's precision approach leverages a proprietary data analytics platform to identify and develop targeted therapies.
Broader Therapeutic Portfolio
Alumis's development pipeline extends beyond envudeucitinib to include A-005, another oral tyrosine kinase 2 (搜索) inhibitor being developed for neuroinflammatory and neurodegenerative diseases (搜索). The company is also advancing lonigutamab, a subcutaneously delivered anti-insulin-like growth factor 1 receptor (搜索) therapy for thyroid eye disease (搜索), along with several preclinical programs identified through their precision approach.
Conference Call Access
The conference call and webcast to discuss the topline data results from the Phase 3 ONWARD clinical program will begin at 8:00 a.m. ET on January 6, 2026. Interested parties can access the live webcast through the company's website at www.alumis.com under the "Events" page of the "Investors" section. A replay of the webcast will be made available on the company's website following the call.